Skip to main content

GeneGo to Develop Data-Management Software for Cystic Fibrosis Foundation

NEW YORK (GenomeWeb News) — GeneGo today said it will work with the Cystic Fibrosis Foundation to develop a software suite to handle data from cystic fibrosis drug-development studies.  
The new platform, called MetaMiner, will include off-the-shelf GeneGo products such as MetaCore, MetaDrug, MetaLink, and MapEditor. MetaMiner will include -omics and small experiments specific to cystic fibrosis that have been annotated by GeneGo.
MetaMiner, which GeneGo plans to use in other collaborations, will be used by researchers conducting high-throughput screens and bioassays, and in this case will be customized for cystic fibrosis experiments.
"We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level," Robert Beall, president and CEO of the Foundation, said in a statement.
Julie Bryant, GeneGo’s vice president of business development, said the collaboration “is the first in a series” of such alliances in which MetaMiner will be used to store and analyze data for disease research.
The platform will be available to the CFF in February, and to other collaborators through access licenses, GeneGo said. A CFF committee will oversee the research.
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.